Example: Heart Attack

Search clinical trials for: Astex Pharmaceuticals

Total 77 results

NCT04466514

Not yet recruiting

A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029

Conditions: Healthy Volunteers
NCT04411030

Recruiting

A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam

Conditions: Healthy Volunteer
NCT04282668

Not yet recruiting

A Study of TAS1440 With ATRA in Subjects With r/r AML

Conditions: Acute Myeloid Leukemia
NCT04256317

Recruiting

A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML

Conditions: Myelodysplastic Syndromes; Chronic Myelocytic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome/Neoplasm
NCT04250246

Not yet recruiting

A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1

Conditions: Melanoma; Non Small Cell Lung Cancer
NCT04155580

Recruiting

A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Conditions: Acute Myeloid Leukemia
NCT04134884

Recruiting

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer; Triple Negative Breast Cancer; Hormone Receptor Positive Tumor
NCT04093570

Enrolling by invitation

An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Conditions: Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes
NCT04061421

Not yet recruiting

A Basket Study of Novel Therapy for Untreated MDS/MPN and Relapsed/Refractory Overlap Syndromes (ABNL-MARRO)

Conditions: MDS/MPN
NCT04013880

Withdrawn

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome
NCT03975387

Recruiting

Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53

Conditions: Solid Tumor
NCT03922555

Recruiting

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Conditions: Neurological Cancer
NCT03913455

Recruiting

Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer

Conditions: Small Cell Lung Cancer; Extensive-stage Small Cell Lung Cancer
NCT03875287

Recruiting

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Subjects With Solid Tumors

Conditions: Solid Tumor
NCT03813186

Completed

Effect of Food on Blood Levels of ASTX727

Conditions: Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia
NCT03603964

Active, not recruiting

Guadecitabine Extension Study

Conditions: Acute Myeloid Leukemia; Myeloid Dysplastic Syndrome
NCT03576963

Recruiting

Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer

Conditions: Colorectal Adenocarcinoma; CpG Island Methylator Phenotype; Metastatic Microsatellite Stable Colorectal Carcinoma; Refractory Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8
NCT03520075

Recruiting

Study of ASTX029 in Subjects With Advanced Solid Tumors

Conditions: Solid Tumor, Adult
NCT03502668

Recruiting

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Conditions: Myelodysplastic Syndromes
NCT03306264

Active, not recruiting

Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML

Conditions: Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia
NCT03220477

Recruiting

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

Conditions: Lung Cancer
NCT03075826

Active, not recruiting

A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

Conditions: Myeloproliferative Neoplasms
NCT02998567

Active, not recruiting

Combination Study of Guadecitabine and Pembrolizumab.

Conditions: Castration-Resistant Prostatic Cancer; Non Small Cell Lung Cancer
NCT02920008

Active, not recruiting

Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia
NCT02907359

Active, not recruiting

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

Conditions: Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic
NCT02901899

Active, not recruiting

Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Conditions: Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
NCT02608437

Unknown status

A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients

Conditions: Metastatic Melanoma
NCT02503423

Recruiting

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Conditions: Solid Tumors; Lymphoma
NCT02348489

Completed

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

Conditions: Leukemia, Myeloid, Acute
NCT02197676

Completed

A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response

Conditions: MDS
NCT02103478

Completed

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral CDAi in Patients With MDS

Conditions: Myelodysplastic Syndrome; MDS
NCT01896856

Completed

Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer

Conditions: Previously Treated Metastatic Colorectal Cancer
NCT01752933

Completed

SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Conditions: Hepatocellular Carcinoma
NCT01712217

Completed

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Conditions: Non-small Cell Lung Cancer(NSCLC)
NCT01696032

Completed

SGI-110 in Combination With Carboplatin in Ovarian Cancer

Conditions: Ovarian Cancer
NCT01685268

Completed

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Conditions: Prostate Cancer
NCT01652144

Completed

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT01627054

Completed

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia

Conditions: Chronic Lymphocytic Leukemia
NCT01357395

Completed

A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer

Conditions: Small Cell Lung Carcinoma
NCT01294202

Completed

A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST

Conditions: Gastrointestinal Stromal Tumor (GIST)
NCT01261312

Completed

SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

Conditions: MDS; CMML; AML
NCT01239108

Withdrawn

Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias

Conditions: Relapsed/Refractory Leukemias
NCT01183949

Completed

Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

Conditions: Multiple Myeloma
NCT01145989

Completed

A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma

Conditions: Multiple Myeloma
NCT00894894

Completed

Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies

Conditions: Solid Tumors
NCT00881166

Completed

Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

Conditions: Malignant Disease
NCT00878423

Completed

Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors

Conditions: Metastatic Solid Tumors
NCT00848601

Terminated

Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma

Conditions: Prostate Cancer; Non-Hodgkins Lymphoma
NCT00571662

Completed

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant

Conditions: Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Lymphocytic Leukemia; Myelodysplastic Syndromes; Multiple Myeloma; Non-Hodgkins Lymphoma; Hodgkins Disease; Peripheral T-cell Lymphoma
NCT00541034

Completed

Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

Conditions: Leukemia; Lymphoma